1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Summary
    PAB   AU000000PAB9


Delayed Australian Stock Exchange  -  01:44 2022-08-11 am EDT
0.0260 AUD    0.00%
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
08/07Patrys Chair to Retire End-August
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Patrys Limited Announces Stable Cell Line for Production of PAT-DX3

02/27/2022 | 04:49pm EDT

Patrys Limited announced it has identified and selected anoptimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows the Company to commence work on developing a commercial scale manufacturing process for GMP-grade (Good Manufacturing Practice) PAT-DX3 deoxymab that is required to commence its clinical development. The establishment of a stable, PAT-DX3-producing cell line is an important milestone that Patrys has achieved ahead of its scheduled timeline. Patrys has established that the selected cell line is both stable and able to deliver reproducible and consistent production of PAT-DX3 protein over time. This cell line will be stored as a Master Cell Bank (MCB) which will form the basis for all future production of PAT-DX3. Studies conducted to date have shown that PAT-DX3 is able to cross the blood brain barrier in animal models of brain cancer and penetrate cancer cells. PAT-DX3 appears to have a higher affinity for DNA than PAT-DX1, suggesting that it has the potential to be more efficacious. In addition, Patrys has reported that PAT-DX3 was able to be used as a targeting agent to successfully deliver an anticancer drug in an animal model of human breast cancer. In view of this potential, the Company is actively exploring partnering opportunities for PAT-DX3 to be used in antibody drug conjugates (ADCs) for the targeted intracellular delivery of cancer drugs and a range of other payloads such as nucleic acids.

© S&P Capital IQ 2022
All news about PATRYS LIMITED
08/10Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
08/07Patrys Chair to Retire End-August
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
07/04Patrys Produces Antibody Drug at Commercial Scale
07/03Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
04/14PATRYS : Application for quotation of securities - PAB
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
More news
Sales 2021 1,34 M 0,95 M 0,95 M
Net income 2021 -4,06 M -2,88 M -2,88 M
Net cash 2021 10,9 M 7,74 M 7,74 M
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 53,5 M 37,9 M 37,9 M
EV / Sales 2020 11,5x
EV / Sales 2021 67,8x
Nbr of Employees 10
Free-Float 70,9%
Duration : Period :
Patrys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, MD & Director
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-26.76%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396